Chloroquine As a Prophylactic Agent Against COVID-19?

Overview

Journal Int J Antimicrob Agents

Specialties Infectious Diseases
Pharmacology

Date 2020 Apr 16

PMID 32294495

Citations 18

Authors

Mathieu Gendrot

Emilie Javelle

Axelle Clerc

Helene Savini

Bruno Pradines

Affiliations

Soon will be listed here.

Citing Articles

Biophysical Analysis of Potential Inhibitors of SARS-CoV-2 Cell Recognition and Their Effect on Viral Dynamics in Different Cell Types: A Computational Prediction from In Vitro Experimental Data.

Gonzalez-Paz L, Lossada C, Hurtado-Leon M, Vera-Villalobos J, Paz J, Marrero-Ponce Y ACS Omega. 2024; 9(8):8923-8939.

PMID: 38434903 PMC: 10905729. DOI: 10.1021/acsomega.3c06968.

Computational investigation of benzalacetophenone derivatives against SARS-CoV-2 as potential multi-target bioactive compounds.

Khanal P, Patil V, Bhandare V, Dwivedi P, Shastry C, Patil B Comput Biol Med. 2022; 146:105668.

PMID: 35667894 PMC: 9135652. DOI: 10.1016/j.compbiomed.2022.105668.

Significance of Immune Status of SARS-CoV-2 Infected Patients in Determining the Efficacy of Therapeutic Interventions.

Saratale G, Shin H, Shinde S, Kim D, Saratale R, Kadam A J Pers Med. 2022; 12(3).

PMID: 35330349 PMC: 8955701. DOI: 10.3390/jpm12030349.

Development and Validation of the Quantification Method for Hydroxychloroquine in Volumetric Absorptive Microsampling (VAMS) Using High-Performance Liquid Chromatography-Photodiode Array.

Harahap Y, Rohadatul Aisy S, Maggadani B Adv Pharmacol Pharm Sci. 2021; 2021:3500279.

PMID: 34632395 PMC: 8497163. DOI: 10.1155/2021/3500279.

Potential drug development and therapeutic approaches for clinical intervention in COVID-19.

Dowarah J, Marak B, Yadav U, Singh V Bioorg Chem. 2021; 114:105016.

PMID: 34144277 PMC: 8143914. DOI: 10.1016/j.bioorg.2021.105016.

References

. [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi. 2020; 43(3):185-188. DOI: 10.3760/cma.j.issn.1001-0939.2020.03.009. View

. Advances in malaria chemotherapy. Report of a WHO Scientific group. World Health Organ Tech Rep Ser. 1984; 711:1-218. View

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M . Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3):269-271. PMC: 7054408. DOI: 10.1038/s41422-020-0282-0. View

Gao J, Tian Z, Yang X . Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020; 14(1):72-73. DOI: 10.5582/bst.2020.01047. View

Rolain J, Colson P, Raoult D . Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents. 2007; 30(4):297-308. PMC: 7126847. DOI: 10.1016/j.ijantimicag.2007.05.015. View

Taylor W, White N . Antimalarial drug toxicity: a review. Drug Saf. 2004; 27(1):25-61. DOI: 10.2165/00002018-200427010-00003. View

Li C, Zu S, Deng Y, Li D, Parvatiyar K, Quanquin N . Azithromycin Protects against Zika virus Infection by Upregulating virus-induced Type I and III Interferon Responses. Antimicrob Agents Chemother. 2019; 63(12). PMC: 6879226. DOI: 10.1128/AAC.00394-19. View

Pages F, Boutin J, Meynard J, Keundjian A, Ryfer S, Giurato L . Tolerability of doxycycline monohydrate salt vs. chloroquine-proguanil in malaria chemoprophylaxis. Trop Med Int Health. 2002; 7(11):919-24. DOI: 10.1046/j.1365-3156.2002.00941.x. View

Peragallo M, Sabatinelli G, Sarnicola G . Compliance and tolerability of mefloquine and chloroquine plus proguanil for long-term malaria chemoprophylaxis in groups at particular risk (the military). Trans R Soc Trop Med Hyg. 1999; 93(1):73-7. DOI: 10.1016/s0035-9203(99)90187-6. View

10.

Zhou P, Huang Z, Xiao Y, Huang X, Fan X . Protecting Chinese healthcare workers while combating the 2019 novel coronavirus. Infect Control Hosp Epidemiol. 2020; 41(6):745-746. PMC: 7184141. DOI: 10.1017/ice.2020.60. View

11.

Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S . A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020; 57:279-283. PMC: 7270792. DOI: 10.1016/j.jcrc.2020.03.005. View

12.

Gautret P, Lagier J, Parola P, Hoang V, Meddeb L, Mailhe M . RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020; 56(1):105949. PMC: 7102549. DOI: 10.1016/j.ijantimicag.2020.105949. View

13.

Michel R, Bardot S, Queyriaux B, Boutin J, Touze J . Doxycycline-chloroquine vs. doxycycline-placebo for malaria prophylaxis in nonimmune soldiers: a double-blind randomized field trial in sub-Saharan Africa. Trans R Soc Trop Med Hyg. 2010; 104(4):290-7. DOI: 10.1016/j.trstmh.2009.10.001. View

14.

Ducharme J, Farinotti R . Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. Clin Pharmacokinet. 1996; 31(4):257-74. DOI: 10.2165/00003088-199631040-00003. View

15.

Touret F, de Lamballerie X . Of chloroquine and COVID-19. Antiviral Res. 2020; 177:104762. PMC: 7132364. DOI: 10.1016/j.antiviral.2020.104762. View

16.

Iannetta M, Ippolito G, Nicastri E . Azithromycin Shows Anti-Zika Virus Activity in Human Glial Cells. Antimicrob Agents Chemother. 2017; 61(9). PMC: 5571307. DOI: 10.1128/AAC.01152-17. View

17.

Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P . In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020; 71(15):732-739. PMC: 7108130. DOI: 10.1093/cid/ciaa237. View